Table 2 Baseline comparison of measured novel biomarkers in the CorLipid population by the presence of coronary syndrome
|
All diabetic patients (n = 316) |
Diabetic patients with ACS (N = 176) |
Diabetic patients with CCS (N = 140) | P-value | |
|---|---|---|---|---|
|
Clinical parameters, Median (IQR = Q3-Q1)]* | ||||
| Acylcarnitine C4 | 41 (736) | 40.6 (735) | 42.5 (423) | 0.87 |
| Acylcarnitine C18:2 | 58 (264) | 54.9 (263) | 61.3 (151) | 0.20 |
| Acylcarnitine ratio C4/C18:2 | 0.72 (12.5) | 0.76 (12.5) | 0.69 (3.4) | 0.41 |
| ApoB | 84.5 (412) | 87.2 (412) | 81.1 (152) | 0.53 |
| ApoA1 | 97.9 (193) | 89.2 (185) | 113 (168) | < 0.01 |
| ΑpoB/ΑpoA1 ratio | 0.79 (6.9) | 0.84 (6.9) | 0.70 (3.2) | 0.02 |
| Ceramide C24:0 | 7.5 (32.7) | 7.4 (28.7) | 7.7 (32.7) | 0.80 |
| Ceramide C24:1 | 3.2 (12.5) | 3.4 (6.7) | 3.1 (12.5) | 0.08 |
| Ceramide ratio C24:1/C24:0 | 0.45 (1.76) | 0.45 (1.76) | 0.42 (1.72) | 0.18 |
| Adiponectin | 162 (215) | 162 (207) | 160 (214) | 0.81 |